Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure
Key facts
- Where
- Fuencarral-El Pardo, SpainSee the site
Where in Spain
- Hospital Universitario La PazFuencarral-El Pardo, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT07260474
- Record updated
- 7 October 2026
- Original description
Clinical investigation with CE-marked medical devices, multicenter, prospective, randomized and controlled. Patients with non-valvular atrial fibrillation at high embolic risk and with at least one high bleeding risk criterion according to the Munich consensus document will be randomized to left atrial appendage closure with either the Amplatzer Amulet™ or the LAmbre™ device. The study is designed to compare the efficacy and safety of both devices regarding successful implantation, effective appendage closure, and clinical outcomes at follow-up.Read full original descriptionShow less
Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure: the CALAMBRE Randomized Clinical Trial
Clinical investigation with CE-marked medical devices, multicenter, prospective, randomized and controlled. Patients with non-valvular atrial fibrillation at high embolic risk and with at least one high bleeding risk criterion according to the Munich consensus document will be randomized to left atrial appendage closure with either the Amplatzer Amulet™ or the LAmbre™ device. The study is designed to compare the efficacy and safety of both devices regarding successful implantation, effective appendage closure, and clinical outcomes at follow-up.
Inclusion: (MUST MEET ALL INCLUSION CRITERIA); Patient with aged ≥18 years AND; Patient have non-valvular atrial (NVAF) with a CHA2DS2-VASc score ≥2, and presented at least one high-bleeding-risk criterion according to the Munich consensus document AND; Patient are required to undergo preprocedural TEE / CCTA to confirm the absence of LAA thrombus and to ensure that LAA anatomy is suitable for closure with either device; Patient who has been informed of the characteristics of the study and has provided written informed consent.
Exclusion: Patient with requirement for oral anticoagulation therapy for any indication other than non-valvular atrial fibrillation; Patient with prior surgical ligation or obliteration of the left atrial appendage; Patient with concurrent participation in another investigational study that may affect study results; Patient life expectancy <1 year (terminal illness); Patient with history of allergic reaction or intolerance to any material used in the study devices or to any of the antithrombotic agents required post-procedure; Patient with active systemic infection; (MUST NOT MEET ANY EXCLUSION CRITERIA); Patient with inability or unwillingness to comply with the study protocol or follow-up requirements; Patient pregnant or breastfeeding women.